Aptamer Details

Back to Search Results

CCRF-CEM (sgc8c) (ID# 7813)

Acute lymphoblastic leukemia (CCRF-CEM)
0.78 nM (reported value)
Binding buffer: 0.1mg/ml yeast tRNA and 1 mg/ml BSA into wash buffer (4.5g/L glucose, 5 mM MgCl2 in Dulbecco's PBS with CaCl2 and MgCl2)
NA If the oligo is a known aptamer sequence: For binding studies, perform a refolding protocol to ensure proper function (i.e. binding to antigen or target). Refer to the aptamer reference source for the appropriate refolding parameters and binding conditions. Note: it is unknown whether aptamer functions properly without refolding.
Recognizes and binds to cell lines Molt-4 (T cell Acute Lymphoblastic Leukemia [ALL]), Sup-T1 (T cell ALL), and Jurkat (T cell ALL).
This aptamer is a truncated version of sgc8.
Huang et al. (2009) conjugated doxorubicin to sgc8c through a hydrazone linker. The sgc8c-doxorubicin conjugate was internalized through receptor-mediated uptake and doxorubicin was released in the endosome. This lead to an increase in toxicity to CCRF-CEM cells of 6.7-fold compared to NB-4 cells. The binding affinity (Kd) of the conjugate was comparable to the unconjugated sgc8c aptamer (2.0 nM).

Note: Information on this aptamer oligo was obtained from the literature and hasn't been validated by Aptagen.

Shangguan et al. "Optimization and Modifications of Aptamers Selected from Live Cancer Cell Lines." Chem. Biochem., 8, (2007): 603-6.

Doxorubicin conjugation:
Y-F Huang et al. Molecular assembly of an aptamer-drug conjugate for targeted drug delivery to tumor cells. Chembiochem. 10(2009):862-868.

Have your aptamer oligo synthesized ORDER